{'fraction_non_alphanumeric': 0.029329608938547486, 'fraction_numerical': 0.023743016759776536, 'mean_word_length': 5.45945945945946, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Current management of melanoma: Benefits of surgical staging and adjuvant therapy

Issues regarding appropriate management of stage I to III melanoma are addressed. Accurate surgical staging is critical to identifying patients who can benefit from therapeutic lymph node dissection and adjuvant therapy. Patients with primary tumors ≥1 mm thick are appropriate candidates for sentinel lymph node biopsy, and node‐positive patients benefit from therapeutic lymphadenectomy. Although the overall survival benefit of high‐dose interferon has been questioned, the weight of evidence supports the use of adjuvant therapy in patients with stage IIB and III disease. J. Surg. Oncol. 2003;82:209–216. © 2003 Wiley‐Liss, Inc.